Navigation Links
Gentium's Defibrotide Highlighted in Two Poster Presentations at,American Association for Cancer Research Annual Meeting

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 13, 2007 - Gentium, S.p.A. (NASDAQ:GENT) (the "Company") today reported that its lead investigational product, Defibrotide, will be the subject of two poster presentations at the American Association for Cancer Research's (AACR) Annual Meeting being held at the Los Angeles Conference Center in Los Angeles, California, from April 14-18, 2007.

On Monday, April 16, 2007, from 1:00 p.m. to 5:00 p.m. (Pacific Time), Dr. Cinara Echart, Ph.D., Manager of Biological Research Laboratory at Gentium, will present a poster entitled "Modulation Of Heparanase Expression In Myeloma Tumor Cell Lines By Defibrotide: A Novel Mechanism Of Anti-Tumor Activity." (Poster session 23, Tumor Biology 21, Abstract #3100, Board #29)

Elevated heparanase expression in humans has been correlated with advanced progression and metastasis of many tumor types, including multiple myeloma (MM), where its presence may be particularly important because MM expresses high levels of heparin sulphate proteoglycan syndecan-1(CD138).

This in vitro study investigated Defibrotide's effectiveness in regulating the expression and activity of heparanase in two MM cell lines, U266 and RPMI 8226. The potential effect of Defibrotide to regulate heparanase gene expression was evaluated through real time polymerase chain reaction (RT-PCR) of cDNA prepared from the two lines of MM cells treated with Defibrotide or saline. Heparanase activity was measured in MM cells treated with Defibrotide (at 50, 100 and 150 (mu)g/ml) or saline for 24 hours by using a heparan-degrading enzyme kit. Results showed a significant down-regulation of heparanase gene expression by Defibrotide (at 150 (mu)/ml) after 24 hours of treatment (p less than 0.01) compared with saline.

Dr. Echart expounded upon these results, "These pre-clinical data suggest that Defibrotide not only has an effect in down-regulation of heparan
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), a ... capital equipment, flat panel, medical, energy and research industries will ... October 24, 2011 after markets close. The Company ... results and management,s outlook at 1:45 pm PDT on Monday, ...
... The medical education landscape has changed dramatically ... pressures have reshaped approaches to Continuing Medical Education ... right staffing, investment, and delivery platforms to provide ... To help inform medical education leaders on ...
Cached Medicine Technology:Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector 2
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... and Infectious Diseases (NIAID), part of the National ... trial of CRS3123, an investigational oral antibiotic intended ... difficile ) infection. CRS3123 (previously known as REP3123) ... growth while sparing normal intestinal bacteria. , The ... healthy men and women ages 18 to 45 ...
(Date:7/9/2014)... on prescription labels handed out by pharmacists may ... taking medication, according to new research by the ... for the Blind)., The study, published recently in ... labels on prescription medications dispensed by pharmacies do ... , By simply following recommended guidelines for font ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... (HealthDay News) -- The percentage of nursing home residents ... is lower than the national goal, and the rate is ... Brown University researchers examined annual patient records from more ... 2008-09. The overall flu vaccination rate for nursing home ...
... NY, October 5, 2011 -- A possible new target ... the Tyk2 protein helps suppress the growth and metastasis ... Interferon & Cytokine Research , a peer-reviewed journal published ... free online for the next week at http://www.liebertpub.com/jir ...
... mid-infrared laser technologies, such as human breath monitoring, ... environmental health monitoring. The meeting will focus on ... The event is hosted by the NSF Engineering ... the Environment (MIRTHE) headquartered at Princeton University. ...
... News) -- Smokers have heart attacks earlier in life than ... suffer complications after a heart attack, according to a new ... the University of Michigan Medical Center from 1999 through 2006 ... patients were current smokers. Male smokers were nine years ...
... in European Physical Journal E (EPJE), a German ... avoid jamming of soft matter that can be applied in ... at the Institute for Material Physics in Space in Cologne, ... be overcome before a solid material made of a metallic ...
... A team of scientists, led by Johns Hopkins researchers, ... how quickly patients with Alzheimer,s disease (AD) will lose ... compounds in their blood. The finding, they say, could ... also suggest treatment targets for this heartbreaking and incurable ...
Cached Medicine News:Health News:Nursing Homes Not Meeting Flu-Shot Goals, Study Says 2Health News:Unlocking jams in fluid materials 2Health News:Blood tests may hold clues to pace of Alzheimer's disease progression 2
Detection of antibodies to Malaria in Human whole blood....
Paracheck Pf is a two site sandwich immunoassay for the detection of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples....
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
Medicine Products: